AXP 1275

Drug Profile

AXP 1275

Alternative Names: AXP1275

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Bayer HealthCare
  • Developer Axikin Pharmaceuticals
  • Class Antiasthmatics; Small molecules
  • Mechanism of Action CCR3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Allergic asthma

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Allergic-asthma(In volunteers) in USA (PO, Capsule)
  • 30 Apr 2014 Axikin Pharmaceuticals completes a phase IIa trial in Allergic asthma in Canada (NCT01890161)
  • 31 Aug 2013 Phase-II clinical trials in Allergic asthma in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top